

# Jose M Garcia

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4428400/publications.pdf>

Version: 2024-02-01

56  
papers

3,342  
citations

218677

26  
h-index

155660

55  
g-index

58  
all docs

58  
docs citations

58  
times ranked

4647  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | The Small Molecule Nobiletin Targets the Molecular Oscillator to Enhance Circadian Rhythms and Protect against Metabolic Syndrome. <i>Cell Metabolism</i> , 2016, 23, 610-621.   | 16.2 | 380       |
| 2  | Sarcopenia, Cachexia and Aging: Diagnosis, Mechanisms and Therapeutic Options - A Mini-Review. <i>Gerontology</i> , 2014, 60, 294-305.   | 2.8  | 338       |
| 3  | Characterization of Adult Ghrelin and Ghrelin Receptor Knockout Mice under Positive and Negative Energy Balance. <i>Endocrinology</i> , 2008, 149, 843-850.  | 2.8  | 235       |
| 4  | Active Ghrelin Levels and Active to Total Ghrelin Ratio in Cancer-Induced Cachexia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 2920-2926.   | 3.6  | 222       |
| 5  | Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. <i>Lancet Oncology</i> , The, 2015, 16, 108-116.   | 10.7 | 176       |
| 6  | Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2015, 6, 132-143.   | 7.3  | 165       |
| 7  | Sex Differences in Muscle Wasting. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1043, 153-197.   | 1.6  | 145       |
| 8  | Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. <i>Supportive Care in Cancer</i> , 2013, 21, 129-137.                           | 2.2  | 141       |
| 9  | Effect on Body Weight and Safety of RC1291, a Novel, Orally Available Ghrelin Mimetic and Growth Hormone Secretagogue: Results of a Phase I, Randomized, Placebo-Controlled, Multiple-Dose Study in Healthy Volunteers. <i>Oncologist</i> , 2007, 12, 594-600. | 3.7  | 115       |
| 10 | Ghrelin Prevents Cisplatin-Induced Mechanical Hyperalgesia and Cachexia. <i>Endocrinology</i> , 2008, 149, 455-460.  | 2.8  | 112       |
| 11 | Low Testosterone Levels and Increased Inflammatory Markers in Patients with Cancer and Relationship with Cachexia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E700-E709.  | 3.6  | 91        |
| 12 | Hypogonadism in male patients with cancer. <i>Cancer</i> , 2006, 106, 2583-2591.   | 4.1  | 88        |
| 13 | Inhibition of Cisplatin-Induced Lipid Catabolism and Weight Loss by Ghrelin in Male Mice. <i>Endocrinology</i> , 2013, 154, 3118-3129.   | 2.8  | 87        |
| 14 | Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2012, 3, 245-251.   | 7.3  | 77        |
| 15 | Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. <i>Growth Hormone and IGF Research</i> , 2009, 19, 267-273.  | 1.1  | 76        |
| 16 | Circulating Inflammatory Cytokines and Adipokines Are Associated With Increased Risk of Barrett's Esophagus: A Case-Control Study. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 229-238.e3.   | 4.4  | 71        |
| 17 | Macimorelin as a Diagnostic Test for Adult GH Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3083-3093.  | 3.6  | 71        |
| 18 | Toll-like receptor 4 mediates Lewis lung carcinoma-induced muscle wasting via coordinate activation of protein degradation pathways. <i>Scientific Reports</i> , 2017, 7, 2273.  | 3.3  | 69        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | A Multibiomarker Risk Score Helps Predict Risk for Barrett's Esophagus. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1267-1271.  | 4.4 | 66        |
| 20 | Rise of Plasma Ghrelin With Weight Loss is Not Sustained During Weight Maintenance. <i>Obesity</i> , 2006, 14, 1716-1723.   | 3.0 | 54        |
| 21 | Use of growth hormone, IGF-I, and insulin for anabolic purpose: Pharmacological basis, methods of detection, and adverse effects. <i>Molecular and Cellular Endocrinology</i> , 2018, 464, 65-74. | 3.2 | 49        |
| 22 | Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1245-1253.  | 1.8 | 45        |
| 23 | Is there an effect of ghrelin/ghrelin analogs on cancer? A systematic review. <i>Endocrine-Related Cancer</i> , 2016, 23, R393-R409.  | 3.1 | 43        |
| 24 | Update on Management of Cancer-Related Cachexia. <i>Current Oncology Reports</i> , 2017, 19, 3.   | 4.0 | 43        |
| 25 | Elimination of Age-Associated Hepatic Steatosis and Correction of Aging Phenotype by Inhibition of cdk4-C/EBP $\beta$ -p300 Axis. <i>Cell Reports</i> , 2018, 24, 1597-1609.                      | 6.4 | 35        |
| 26 | Ghrelin deletion protects against age-associated hepatic steatosis by downregulating the C/EBP $\beta$ -p300/DGAT1 pathway. <i>Aging Cell</i> , 2018, 17, e12688.                                 | 6.7 | 32        |
| 27 | Clinical development of ghrelin axis-derived molecules for cancer cachexia treatment. <i>Current Opinion in Supportive and Palliative Care</i> , 2013, 7, 368-375.                                | 1.3 | 27        |
| 28 | Ghrelin Partially Protects Against Cisplatin-Induced Male Murine Gonadal Toxicity in a GHSR-1a-Dependent Manner. <i>Biology of Reproduction</i> , 2015, 92, 76.                                   | 2.7 | 26        |
| 29 | Deletion of ghrelin prevents aging-associated obesity and muscle dysfunction without affecting longevity. <i>Aging Cell</i> , 2017, 16, 859-869.  | 6.7 | 26        |
| 30 | Ghrelin Prevents Cisplatin-Induced Testicular Damage by Facilitating Repair of DNA Double Strand Breaks Through Activation of p53 in Mice. <i>Biology of Reproduction</i> , 2015, 93, 24.         | 2.7 | 25        |
| 31 | Preoperative cancer cachexia and short-term outcomes following surgery. <i>Journal of Surgical Research</i> , 2016, 205, 398-406.   | 1.6 | 22        |
| 32 | Whole-body and adipose tissue metabolic phenotype in cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 1124-1133.  | 7.3 | 17        |
| 33 | What is next after anamorelin?. <i>Current Opinion in Supportive and Palliative Care</i> , 2017, 11, 266-271.   | 1.3 | 16        |
| 34 | Evaluation of physical function and its association with body composition, quality of life and biomarkers in cancer cachexia patients. <i>Clinical Nutrition</i> , 2021, 40, 978-986.             | 5.0 | 16        |
| 35 | Cancer-driven changes link T cell frequency to muscle strength in people with cancer: a pilot study. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 827-843.                       | 7.3 | 15        |
| 36 | Evaluation of Veterans MOVE! Program for Weight Loss. <i>Journal of Nutrition Education and Behavior</i> , 2016, 48, 299-303.e1.  | 0.7 | 14        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | A bladder cancer patient-derived xenograft displays aggressive growth dynamics in vivo and in organoid culture. <i>Scientific Reports</i> , 2021, 11, 4609.   | 3.3 | 14        |
| 38 | Ghrelin ameliorates tumor-induced adipose tissue atrophy and inflammation via Ghrelin receptor-dependent and -independent pathways. <i>Oncotarget</i> , 2020, 11, 3286-3302.  | 1.8 | 14        |
| 39 | The habenula as a novel link between the homeostatic and hedonic pathways in cancer-associated weight loss: a pilot study. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 497-504.  | 7.3 | 12        |
| 40 | Assessing Cachexia Acutely after Autologous Stem Cell Transplant. <i>Cancers</i> , 2019, 11, 1300.  | 3.7 | 11        |
| 41 | Growth hormone secretagogue receptor-1a mediates ghrelin's effects on attenuating tumour-induced loss of muscle strength but not muscle mass. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 1280-1295.  | 7.3 | 8         |
| 42 | Editorial: Neuroendocrine Disorders After Traumatic Brain Injury: Past, Present and Future. <i>Frontiers in Endocrinology</i> , 2019, 10, 386.  | 3.5 | 7         |
| 43 | Appendicular Lean Mass, Grip Strength, and the Development of Hospital-Associated Activities of Daily Living Disability Among Older Adults in the Health ABC Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2022, 77, 1398-1404. | 3.6 | 7         |
| 44 | Cannabinoids in Patients with Nausea and Vomiting Associated with Malignancy and Its Treatments. <i>American Journal of Medicine</i> , 2018, 131, 755-759.e2.   | 1.5 | 6         |
| 45 | Muscle mass, not radiodensity, predicts physical function in cancer patients with or without cachexia. <i>Oncotarget</i> , 2020, 11, 1911-1921.   | 1.8 | 6         |
| 46 | Off-Label Megestrol in Patients with Anorexia-Cachexia Syndrome Associated with Malignancy and Its Treatments. <i>American Journal of Medicine</i> , 2018, 131, 623-629.e1.   | 1.5 | 5         |
| 47 | Experience of a Pituitary Clinic for US Military Veterans With Traumatic Brain Injury. <i>Journal of the Endocrine Society</i> , 2021, 5, bvab005.  | 0.2 | 5         |
| 48 | Omega-3 Fatty Acids in Patients with Anorexia-Cachexia Syndrome Associated with Malignancy and Its Treatments. <i>American Journal of Medicine</i> , 2017, 130, 1151-1155.  | 1.5 | 4         |
| 49 | Management of Opioid-Induced Constipation in Patients with Malignancy. <i>American Journal of Medicine</i> , 2018, 131, 1041-1051.e3.   | 1.5 | 3         |
| 50 | Androgens and estrogens predict sexual function after autologous hematopoietic stem cell transplant in men. <i>Andrology</i> , 2022, 10, 291-302.   | 3.5 | 3         |
| 51 | Nonsteroidal Anti-Inflammatory Drugs in Patients with Anorexia-Cachexia Syndrome Associated with Malignancy and Its Treatments. <i>American Journal of Medicine</i> , 2017, 130, 1033-1036.   | 1.5 | 2         |
| 52 | Gout and open-angle glaucoma risk in a veteran population. <i>Graefes Archive for Clinical and Experimental Ophthalmology</i> , 2021, 259, 3371-3379.   | 1.9 | 2         |
| 53 | High-Dose Benzodiazepine Therapy in Hospitalized Anxious Patients. <i>Journal of Clinical Pharmacology</i> , 1983, 23, 100-105.   | 2.0 | 1         |
| 54 | Reversible Adrenal Insufficiency in Three Patients With Post-Roux-en-Y Gastric Bypass Noninsulinoma Pancreatogenous Hypoglycemia Syndrome. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2014, 2, 232470961452699.                                      | 0.6 | 1         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Clinical research in older adults with hematologic malignancies: Opportunities for alignment in the Veterans Affairs. <i>Seminars in Oncology</i> , 2019, 46, 341-345.                                       | 2.2 | 0         |
| 56 | Testosterone replacement for fatigue in male hypogonadic patients with advanced cancer: A preliminary double-blind placebo-controlled trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, e19643-e19643. | 1.6 | 0         |